Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Other Female Genital, Ovary,
• Age: Between 18 Year(s) - 99 Year(s)
• Gender: Female

• Other Inclusion Criteria:
  

  In order to participate in this study the following conditions must be met:

  1. Female participants aged 18 years or older at the time of signing the ICF
  2. Histological diagnosis of a high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  3. Have platinum-resistant disease: a. Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of a platinum-containing regimen, had a response (CR or PR) or had nonmeasurable disease at the start of the platinum-based therapy, and then progressed between > 3 and = 6 months after the last dose of platinum. b. Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.
  4. CCNE overexpression noted in tumor tissue anlaysis

  
  

You may not be eligible for this study if the following are true:

• You will not be able to participate in this study if you have:

  1. Have endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer.
  2. Have primary platinum-refractory disease: either did not respond (CR or PR) to first-line platinum-containing therapy or progressed on or within 3 months after the last dose of the first-line platinum-containing therapy.
  3. The tumor tests positive for FRa but the participant has not received mirvetuximab, soravtansine due to it being unavailable.